Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash as Part of Compensation
SEC Form 4 Filing
A Form 4 filing reveals Agenus Inc. CEO Garo H. Armen received 4,207 shares of common stock as part of his compensation in lieu of cash.
Summary
- A Form 4 filing indicates that Agenus Inc.'s CEO, Garo H. Armen, received 4,207 shares of common stock on November 1, 2024, as part of his compensation.
- This stock was issued in lieu of cash salary for the pay period ending on that date, with the shares valued at $4.05 each, which was the closing price of Agenus's common stock on November 1, 2024.
- The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive and are fully vested upon issuance.
- Following this transaction, Dr. Armen directly owns 102,327 shares.
- Dr. Armen also indirectly owns 31,298 shares through his IRA accounts and 28,950 shares as trustee and investment authority for the Garo Armen 2020 2 Year AG GRAT and as a general partner in Pixie Partners.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction related to executive compensation. The acceptance of stock in lieu of cash could be seen as a positive sign of confidence, but it's not definitively bullish.
Positives
- The CEO's acceptance of stock in lieu of cash may indicate confidence in the company's future performance.
- The use of the equity incentive plan aligns the CEO's interests with those of the shareholders.
Industry Context
Stock-based compensation is a common practice in the biotech industry to conserve cash and align executive incentives with shareholder value. This is especially true for companies like Agenus that are in the development stage.
Comparison to Industry Standards
- Stock compensation for CEOs in biotech varies widely depending on the company's size, stage of development, and financial performance.
- Comparing Agenus's compensation structure to peers like Iovance Biotherapeutics, Gritstone Bio, or BioNTech would provide a better understanding of whether this is above or below industry standards.
Stakeholder Impact
- Shareholders may view the CEO's acceptance of stock as a positive sign, aligning his interests with theirs.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2019 | Amended and Restated Agenus Inc. 2019 Equity Incentive Plan |
| November 1, 2024 | Date of transaction: Garo H. Armen received 4,207 shares of common stock at $4.05 per share. |
| November 4, 2024 | Date of filing of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.